ANN ARBOR, MI – WEDNESDAY, DECEMBER 1, 2021
Ripple Science, a leading clinical trial technology company focused on improving clinical trial recruitment and retention, announced today that it has appointed Robert Conklin as its Chief Technology Officer (CTO).
Mr. Conklin, a senior technology executive with over 15 years of experience leading teams building healthcare technology products, joins Ripple with the goal of building a technology platform to accelerate the time it takes to bring discoveries to market by addressing the two biggest problems facing the clinical trial industry, recruitment and retention. As the CTO, Rob will be responsible for implementing strategy and leading innovation to drive product development based on industry needs at scale.
“We are excited to welcome Rob to Ripple Science. He was undoubtedly the best choice for the role, as he brings exceptional expertise in building and leading teams, driving innovation and has an outstanding track record of developing technology products that customers love.” said Peter Falzon, President and CEO of Ripple Science. “Rob’s keen abilities in developing transformation roadmaps in our highly regulated industry will lead us to delivering clinical research technology that addresses that ‘middle piece’ in the clinical research process between identifying a potential participant and enrolling them in a study.
Prior to joining Ripple Science, Mr. Conklin spent 10 years at Ann Arbor technology leader ProQuest in roles of increasing responsibility building innovative products and product development teams. Having worn the developer and architect hats, Mr. Conklin brings a hands-on approach to managing that is particularly valuable to a revenue generating startup.
“I’m enthusiastic to join the management team at Ripple Science and contribute to the mission of making research better, faster, and smarter through technology.” Mr. Conklin said. “Ripple’s enthusiastic users are every day validating the need for the direct-to-patient platform to successfully enroll and man